Keywords:
Eyes, CNS, MR, Stereotactic radiotherapy, Radiation therapy / Oncology, Neoplasia
Authors:
G. Ratnayake, T. Oh, R. Mehta, T. Hardy, K. Woodford, R. Haward, J. Ruben, M. Dally; VIC/AU
DOI:
10.26044/ranzcr2019/R-0013
Methods and materials
Patients with a diagnosis of primary ONSM were extracted from a prospective institutional database between January 2004 and December 2013. Patients with meningiomas of the sphenoid wing or planum sphenoidale with secondary involvement of the optic nerve were excluded.
Patients were treated with radiotherapy with multiple non-coplanar dynamic conformal technique using a Novalis TX linear accelerator with ExacTrac image guidance. Treatment doses varied from a mildly hypofractionated approach of 37.5 Gy in 15 fractions to conventionally fractionated 50.4-54 Gy in 28-30 fractions, prescribed to the 90 to 95% covering isodose line treating with 5 fractions per week.
Toxicities were retrospectively obtained from descriptive medical records and graded according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE).
Ophthalmological follow up included assessment of symptoms (e.g. visual function, pain, diplopia), best corrected visual acuity (BCVA), ocular motility assessment, visual fields, exophthalmometry readings and optic disc assessment.
Patients were assessed weekly during their treatment and annually thereafter. Upon completion of treatment all patients had regular 12 to 24 monthly follow up.